Mylan and Theravance Biopharma’s COPD treatment gets FDA approval

Nov 9 (Reuters) – Theravance Biopharma Inc and partner Mylan NV on Friday won U.S. regulatory approval for their treatment for a chronic lung condition that causes breathing-related problems.

The treatment, Yupelri https://www.accessdata.fda.gov/drugsatfdatdocs/label/2018/210598s000lbl.pdf, is once-daily inhalable solution to be used by patients of chronic obstructive pulmonary disease (COPD), a lung disease characterized by wheezing or chronic cough. (Reporting by Manogna Maddipatla in Bengaluru; Editing by Maju Samuel)

About CNBC Wire

CNBC Wire content are post from the wire section of CNBC. May not be edited.
View all posts by CNBC Wire →